TABLE 1.

Strains used in this study and their relevant phenotypes

Strain	Species	Source or derivation	Phage type	MIC (μg/ml)a
				AMP	CEF	CXM	CTX	CRO	CFP	ATM	CAZ	FOX	CTT	ESBL test		NAL	CIP	SPX	NOR	OFX
														CTX	CTL
Hd63	S. Enteritidis	Clinical isolate	6a	>256	>256	>256	256	>256	>256	2	1.5	3	0.094	>16	0.125	>256	0.19	0.25	1	1
Hd92	S. Enteritidis	Hd63 derivative lacking pS12 and pS12-1	1	1	2	2	0.047	0.047	0.5	0.047	0.19	2	0.094	NTb	NT	>256	0.19	0.19	0.5	1
DH10B	E. coli	Purchased from Invitrogen		2	8	2	0.032	0.023	0.047	0.032	0.19	4	0.19	NT	NT	1.5	0.002	<0.002	0.016	0.008
Hd90	E. coli	DH10B transformant of pS12		>256	>256	>256	256	256	256	4	1.0	3	0.19	>16	0.064	1.5	0.002	<0.002	0.016	0.008
Hd91	E. coli	DH10B transformant of pS12-1		>256	>256	>256	256	256	256	3	0.75	3	0.19	>16	0.064	0.75	0.002	<0.002	0.016	0.008
Hd47	S. Enteritidis	Clinical isolate	1	1.5	3	3	0.094	0.094	0.75	0.032	0.25	2	0.094	NT	NT	>256	0.25	0.25	0.75	0.75
Hd93	S. Enteritidis	Transconjugant of Hd47 with Hd90	6a	>256	>256	>256	256	>256	>256	3	2	2	0.094	>16	0.094	>256	0.19	0.19	0.5	0.75

^aDetermined by E test. AMP, ampicillin; CEF, cephalothin; CXM, cefuroxime; CTX, cefotaxime; CRO, ceftriaxone; CFP, cefoperazone; ATM, aztreonam; CAZ, ceftazidime; FOX, cefoxitin; CTT, cefotetan; CTL, cefotaxime plus clavulanic acid; NAL, nalidixic acid; CIP, ciprofloxacin; SPX, sparfloxacin; NOR, norfloxacin; OFX, ofloxacin.

^bNT, not tested.